A phase II, open-label, multicentre study to evaluate the immunogenicity and safety of an adjuvanted prepandemic (H5N1) influenza vaccine in healthy Japanese adults
<p>Abstract</p> <p>Background</p> <p>Promising clinical data and significant antigen-sparing have been demonstrated for a pandemic H5N1 influenza split-virion vaccine adjuvanted with AS03<sub>A</sub>, an α-tocopherol-containing oil-in-water emulsion-based Ad...
Main Authors: | Dramé Mamadou, Maeda Atsushi, Tenjinbaru Kazuyoshi, Ikematsu Hideyuki, Nagai Hideaki, Roman François P |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-11-01
|
Series: | BMC Infectious Diseases |
Online Access: | http://www.biomedcentral.com/1471-2334/10/338 |
Similar Items
-
Evaluation of immune response following one dose of an AS03A-adjuvanted H1N1 2009 pandemic influenza vaccine in Japanese adults 65 years of age or older
by: Hideyuki Ikematsu, et al.
Published: (2012-08-01) -
Development and characterization of standard reagents for cell-based prepandemic influenza vaccine products
by: Chia-Chun Lai, et al.
Published: (2020-09-01) -
IMMUNOGENICITY OF ADJUVANT INFLUENZA VACCINE FOR PREGNANT WOMEN
by: M. P. Kostinov, et al.
Published: (2017-06-01) -
Immunogenicity of an adjuvanted broadly active influenza vaccine in immunocompromised and diverse populations
by: Dylan A. Hendy, et al.
Published: (2024-03-01) -
Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
by: Waddington, C, et al.
Published: (2010)